Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
HUMAN janus kinase 1 (JAK-1) |
Target Info
|
Inhibitor |
[3], [4] |
| HUMAN janus kinase 2 (JAK-2) |
Target Info
|
Inhibitor |
[3], [4] |
| References |
Top |
| REF 1 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
|
| REF 2 |
Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
|
| REF 3 |
The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
|
| REF 4 |
FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 202192
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
